Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer

Akash K. Kaushik,†,‡,§,△ Shaiju K. Vareed,†,‡,△ Sumanta Basu,† Vasanta Putluri,‡,§ Nagireddy Putluri,‡,§ Katrin Panzitt,‡,§ Christine A. Brennan,† Arul M. Chinnaiyan,§ Ismael A. Vergara,△ Nicholas Erho,△ Nancy L. Weigel,§ Nicholas Mitiades,§ Ali Shojaie,□ Ganesh Palappatu,§ George Michailidis,∥ and Arun Sreekumar†,‡,§,○,*

†Verna and Marrs McLean Department of Biochemistry and Molecular Biology, ‡Alkek Center for Molecular Discovery, §Molecular and Cellular Biology, and ‖Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, United States
△Department of Statistics, ‡Department of Urology, and §Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States
□Department of Biostatistics, University of Washington, Seattle, Washington 98195, United States.
©Genome Dx Biosciences, Inc., Vancouver, BC V6B 1B8, Canada

ABSTRACT: Despite recent developments in treatment strategies, castration-resistant prostate cancer (CRPC) is still the second leading cause of cancer-associated mortality among American men, the biological underpinnings of which are not well understood. To this end, we measured levels of 150 metabolites and examined the rate of utilization of 184 metabolites in metastatic androgen-dependent prostate cancer (AD) and CRPC cell lines using a combination of targeted mass spectrometry and metabolic phenotyping. Metabolic data were used to derive biochemical pathways that were enriched in CRPC, using Oncomine concept maps (OCM). The enriched pathways were then examined in-silico for their association with treatment failure (i.e., prostate specific antigen (PSA) recurrence or biochemical recurrence) using published clinically annotated gene expression data sets. Our results indicate that a total of 19 metabolites were altered in CRPC compared to AD cell lines. These altered metabolites mapped to a highly interconnected network of biochemical pathways that describe UDP glucuronosyltransferase (UGT) activity. We observed an association with time to treatment failure in an analysis employing genes restricted to this pathway in three independent gene expression data sets. In summary, our studies highlight the value of employing metabolomic strategies in cell lines to derive potentially clinically useful predictive tools.

KEYWORDS: prostate cancer, castration-resistant prostate cancer, metabolomics, metabolic phenotyping, liquid chromatography—mass spectrometry, Oncomine concept map, biochemical recurrence

INTRODUCTION

Prostate cancer (PCa) is the second leading cause of cancer-related death among men in the United States. For over 50 years, PCa has been known to be an androgen-dependent disease. Clinically localized disease can be effectively treated with either surgery or radiation. Metastatic disease, however, while initially responsive to androgen ablative therapy, often evolves into a castration-resistant state that is incurable and leads to cancer-associated death. Androgen ablation therapy leads to substantial apoptosis of androgen-dependent cells and tumor regression. In ~20–35% of cases, however, the tumor recurs within 5 years. There is compelling evidence that these recurrent tumors, termed castration resistant PCa (CRPC), continue to require androgen receptor (AR) signaling, despite the reduction in levels of circulating androgens. Like many advanced tumors, CRPC develops in the background of diverse genetic and environmental factors. Distinct sets of genes, proteins, and metabolites are thought to dictate progression from an androgen-dependent phenotype to a castration-resistant state. Since AR is a transcription factor, many investigators have sought to identify androgen-regulated genes within PCa cells and tissues. Remarkably, little is known about the genes regulated by AR in the CRPC state.

Because of multiple levels of regulation in gene activity, including translation and post-translational modifications to modify protein activity, changes in mRNA often do not correlate directly with changes in protein expression and function. Another challenge in examining gene function is pathway redundancy. Nevertheless, despite pathway compensation, subtle alterations in enzymatic activity can lead to meaningful changes in levels of metabolites required for tumor growth. Multiple groups have interrogated androgen-regulated changes at the transcriptome and proteome levels in PCa cell...
lines, using gene expression arrays and mass spectrometry.\textsuperscript{12,13} One such seminal study using Affymetrix oligonucleotide arrays highlighted the association of androgen signaling in PCA cells with metabolic processes associated with stress responses.\textsuperscript{14} Furthermore, androgen-driven proliferation of PCA cells has been shown to involve activation of mammalian target of rapamycin (m-TOR), which itself is sensitive to metabolic perturbations in the tumor.\textsuperscript{15–17} Until recently, means to perform large scale profiling of metabolites, which are critical effectors of cellular functions, have not been available. Using an integrative analysis of matched gene expression and proteomic data, in earlier work we predicted the activation of amino acid metabolism in androgen-treated LNCaP (androgen-sensitive) prostate cancer cells.\textsuperscript{18} This expectation was further strengthened by metabolomic profiling of PCA tissues that revealed amino acid metabolism as being one of the hallmarks of early tumor development.\textsuperscript{19} In this tissue-based profiling study, a comparative analysis of the levels of 1,126 metabolites using high-throughput liquid and gas chromatography-based mass spectrometry was able to distinguish between benign prostate, organ-confined PCA and metastatic disease. This study delineated metabolic profiles associated with metastasis and CRPC. Due to the lack of same patient pre- and post-treatment samples, there have been no studies thus far that have addressed the metabolic changes that occur during the transition of an androgen-dependent metastatic cells to a castration-resistant stage, wherein a reprogrammed androgen receptor signaling is hypothesized to be a major driver of cellular growth and survival. Here, using well characterized cell line models for metastatic androgen-dependent and castration-resistant disease, we have characterized metabolic profiles using mass spectrometry and nominated predictive pathways associated with PSA recurrence after radical prostatectomy for localized prostate cancer (i.e., biochemical recurrence (BCR)). Our results suggest a strong association of metabolic processes associated with UDP-glucuronosyltransferases activity as well as starch, sucrose, and histidine metabolism with BCR. Importantly, a distinguishing feature of our approach is the combination of mass spectrometry, bioinformatics, and metabolic phenotyping with a novel prognosis-associated data mining strategy. In this way, we were able to define a CRPC cell line-derived, pathway-centric metabolic signature, with verified activity that is associated with patient-related clinical outcome.

\section*{MATERIALS AND METHODS}

\textbf{Cell Lines}

Prostate-derived cell lines (androgen receptor positive, LNCaP and MDA-PCa-2a and MDA-PCa-2b; and castration-resistant (CRPC), C4-2, 22Rv1 and LNCaP-abl) were used for this study. Of these, MDA-PCa-2a and MDA-PCa-2b were gifts from Dr. Nora Navone, LNCaP-abl from Dr. Nicholas Mitsiades and C4-2 were originally purchased from UroCor by Dr. Nancy Weigel; the remaining cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). LNCaP and 22Rv1 were grown in RPMI-1640 media (Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Hypcclone Laboratories, Rockford, IL) and 1% penicillin-streptomycin (Hyclone Laboratories, Thermo Scientific, Rockford, IL). C4-2 cells were grown in T-media (Gibco) supplemented with 5% FBS and 1% penicillin-streptomycin (Hyclone Laboratories, Thermoscientific, Rockford, IL). LNCaP-abl cells were grown in RPMI-1640 media (Invitrogen Corp., Carlsbad, CA) lacking phenol red supplemented with 10% charcoal stripped FBS and 1% penicillin-streptomycin (Hyclone Laboratories, Thermo Scientific, Rockford, IL). MDA-PCa-2a and MDA-PCa-2b were grown in BRFF-HPC1 medium (Athena ES company cat. no. 0403) with 20% FBS, gentamicin (GIBCO cat. no. 15750-060, final concentration 50 μg/mL) and FNC coating mix solution (Athena ES cat. no. 0407). All cells were maintained at 37 °C and 5% CO\textsubscript{2} and regularly monitored for mycoplasma using MycoAlert (Lonza, Anaheim, CA). Prior to their analyses, cells were trypsinized, and the pellet was washed thrice with ice-cold PBS, separated into aliquots of 5 million cells, and stored at −140 °C.

\textbf{Mass Spectrometry}

\textbf{Reagents and Internal Standards.} High-performance liquid chromatography (HPLC) grade acetonitrile, methanol, and water were purchased from Burdick & Jackson (Morristown, NJ). Mass spectrometry grade formic acid and internal standards, namely, N-acetyl aspartic acid-\textsuperscript{15N},-tryptophan, sarcosine-\textsuperscript{14}C, glutamic acid-\textsuperscript{14}C, thymine-\textsuperscript{15N}, glibberelic acid, trans-zeatin, jasmonic acid, \textsuperscript{15N}-anthranilic acid, and testosterone-\textsuperscript{14}C were purchased from Sigma-Aldrich (StLouis, MO). ESI-L Low Concentration Tuning Mix (Part No. G1969-85000) from Agilent Technologies (Santa Clara) was used to calibrate the mass spectrometer.

\textbf{Liquid Chromatography–Mass Spectrometry.} HPLC analysis was performed using an Agilent 1260 series HPLC system equipped with a degasser, binary pump, thermostat autosampler, and column oven (all from Agilent Technologies, Santa Clara, CA). The multiple reaction monitoring (MRM)-based measurement of levels of 150 metabolites was performed using 12 different methods that used either a reverse phase (RP) or aqueous normal phase (ANP) chromatographic separation, prior to mass spectrometry (Supporting Information Table S1). Details of the methods, associated chromatographic conditions, metabolites measured, and their corresponding MRM transitions are given in Supporting Information Table S1. For reverse phase separation, a Zorbax Eclipse XDB-C18 column (50 mm × 4.6 mm i.d.; 1.8 μm particle size, Agilent Technologies, Santa Clara, CA) maintained at 37 °C was used. The mobile phase used for the RP separation contained 0.1% formic acid/water (v/v; A) and 0.1% formic acid/acetonitrile (v/v; B). The gradient conditions were 0–6 min 2% B; 6.5 min 30% B; 7 min 90% B; 12 min 95% B followed by re-equilibration to the initial starting condition. The flow rate throughout the separation was maintained at 0.2 mL/min. For ANP separation, a Diamond-Hydride column (100 m × 2.1 mm i.d.; 4.2 μm particle size, Microsource Technology Corporation, Eatontown, NJ) maintained at 37 °C, was used. The mobile phase used for the RP separation contained 0.1% formic acid/water (v/v; A) and 0.1% formic acid/acetonitrile (v/v; B). The gradient conditions were 0–2 min 95% B; 3 min 90% B; 5 min 80%; 6–7 min 75% B; 8 min 55% B; 10 min 40% B; 12 min 30% B; 14 min 20% B followed by re-equilibration to the initial starting condition. The flow rate was gradually increased during the separation from 0.5 mL/min (0–8 min) to 0.7 mL/min (10–14 min) and finally set at 0.8 mL/min (15–17 min). The total run time was set to 20 min. The samples were kept at 4 °C, and a constant volume of 5 μL was injected for analysis. The mass
spectrometric analysis was performed on a 6430 QQQ-LC/MS (Agilent Technologies, Santa Clara, CA). The mass spectrometer was operated in both electrospray (ESI) positive and negative ionization modes, with a capillary voltage of 3000 V, a collision gas flow rate of 10 L/min, and a nebulizer gas flow rate of 35 L/min. The temperature of the nebulizer gas was maintained at 350 °C. Nitrogen was used as the collision gas at a collision cell pressure of 2.39 × 10⁻⁵ Torr. For maximum sensitivity, the fragmentor voltage and collision energy for each metabolite were optimized separately using the optimizer software (Agilent Technologies, Santa Clara, CA), and the optimized values were used for the multiple reaction monitoring (MRM) assays. A list of MRM transitions and HPLC methods used for each metabolite measured in this study is given in Supporting Information Table S1.

**Internal Standard Solution and Quality Controls.** Aliquots (200 μL) of 10 mM solutions of N-acetyl aspartic acid-δ₉, [¹⁵N]₃-tryptophan, sarcosine-δ₉, glutamic acid-δ₉, thymine-δ₉, gibererlic acid, trans-zeatin, jasmonic acid, [¹⁵N]-anthranilic acid, and testosterone-δ₉ were mixed and diluted up to 8000 μL (final concentration 0.25 mM) and aliquoted into 20 μL portions. The aliquots were dried and stored at −80 °C. Two kinds of controls were used to monitor the sample preparation and mass spectrometry. To monitor instrument performance, 20 μL of a matrix-free mixture of the internal standards described above, reconstituted in 100 μL of methanol/water (50:50) was analyzed by MRM. In addition, the process of metabolite extraction from the cell lines was monitored using pooled liver samples and spiked internal standards. In the case of the former, 100 mg of pooled liver was extracted in tandem with the cell lines using buffer containing spiked internal standards as described above. In addition, internal standards were also spiked into cell lines during the extraction process. The matrix-free internal standards and liver samples were analyzed twice daily.

**Sample Preparation for Mass Spectrometric Analysis.** The metabolome extraction method described earlier was used for the cell lines and pooled liver controls in this study. Briefly, cells were thawed at 4 °C and subjected to freeze–thaw cycles in liquid nitrogen and over ice three times to rupture the cell membrane. Following this, 750 μL of ice-cold methanol/water (4:1) containing 20 μL of spiked internal standards was added to each cell line. The cells were homogenized for 1 min (30 s pulse twice), mixed with 450 μL of ice-cold chloroform, and vortexed mixed in a Multi-Tube Vortexer for 10 min. The homogenate was mixed with 150 μL of ice-cold water and vortexed again for 2 min. The homogenate was incubated at −20 °C for 20 min and centrifuged at 4 °C for 10 min to partition the aqueous and organic layers. The aqueous and organic layers were separated and dried at 37 °C for 45 min in an Automatic Environmental Speed Vac system (Thermo Fisher Scientific, Rockford, IL). The aqueous extract was reconstituted in 500 μL of ice-cold methanol/water (50:50) and filtered through 3 KDa molecular filter (Amicon Ultrace 3K Membrane, Millipore Corporation, Billerica, MA) at 4 °C for 90 min to remove proteins. The filtrate was dried at 37 °C for 45 min in a speed vac and stored at −80 °C until mass spectrometry analysis. Prior to mass spectrometry analysis, the dried extract was resuspended in 100 μL of methanol/water (50:50) containing 0.1% formic acid and analyzed using MRM.

**Metabolic Phenotyping Microarray.** Global carbon utilization profiles were evaluated by using Biolog Phenotyping Microarray (PM) MicroPlate (Biolog, Inc., Hayward, CA). PM technology is a high-throughput technology for testing the metabolic status of a cell line. The assay is performed in a 96-well format where each well contains a different metabolite. Utilization of the specific metabolite within the cell is detected colorimetrically by a tetrazolium-based redox dye. Reduction of this dye by reduced nicotinamide adenine dinucleotide (NADH) produced due to the utilization of the metabolite by the cells results in formation of specific color. The assay was performed as per manufacturer’s instructions. Briefly, cells were counted, pelleted, and resuspended in inoculation medium (M1 medium), and then 50 μL of the cell suspension containing 2 × 10⁴ cells/well was transferred into the plates and incubated at 37 °C in a humidified atmosphere with 5% CO₂ for 24 h. The next day, 10 μL of redox dye (dye A) was added per well, and plates were kept in the Biolog reader at 37 °C. Absorbance was measured automatically every 15 min for 3.5 h using an OmniLog incubator reader.

**Data Analysis of Mass Spectrometry and Metabolic Phenotyping microarray.** The MRM-based mass spectrometry data were log2 transformed and four normalization methods were used: (1) scaling by spiked internal standard ([¹⁵N]₃-tryptophan), (2) centering and scaling using the median and the interquartile range of all the spiked internal standards, (3) centering and scaling using the median and the interquartile range for the entire data set, and (4) centering and scaling of the metabolites using the median and interquartile range corresponding to each of the 12 methods used. To visualize results of each of these normalization methods, heat maps were drawn using the “gplots” package in the R-software language. To compute the differentials, for each of the above normalization methods, data obtained from different platforms were z-transformed and compared across samples. A two-sided t test was used to assess the association of each metabolite with AD or CRPC status of the samples. Significance was determined by calculating the null distribution based on 10,000 permutations of the group labels, and the resulting p-values were then adjusted for multiple testing using FDR methodology, computed using the R-package fdrtool. Results were visualized using a complete linkage hierarchical clustering function, which uses the Euclidean distances in the data.

**Core CRPC Metabolic Signature and Bioprocess Mapping.** As described above, the metabolite data for the AD and CRPC cell lines were normalized using four different methods. Following this, the list of metabolites that were commonly altered between AD and CRPC lines, across all four normalization methods, at two FDR thresholds, 6% and 20%, were derived. The latter threshold was used to describe metabolite-level changes between AD and CRPC, while the former, termed core CRPC-associated metabolic signature (CCAMS), was used for Oncmine concept map (OCM)-based bioprocess enrichment, as described below. In parallel to
determine metabolic alterations and pathways between AD and CRPC cells of the same parental origin, we compared the metabolome of LNCaP (AD) with C42 and LNCaP-abl (both CRPC). As described earlier, the data was normalized using four different methods, and the commonly altered metabolites at FDR 20% were used to enrich for bioprocesses using OCM.

For the OCM bioprocess enrichment, metabolites in the CCAMS or those that were altered in LNCaP vs C42 and LNCaP-abl comparison were converted to enzyme-coding genes using matched KEGG data sets (KEGG API version v6.2, containing a total of 4435 enzyme coding genes and 1405 corresponding metabolites). In parallel, to generate a null set, all of the metabolites identified in this study (n = 150) were also converted to their respective enzyme-coding genes. As the first step toward this, in the CCAMS signature, 17/19 mapped to their respective KEGG IDs while only 124/150 (82.66%) metabolites in the entire data set mapped to unique KEGG IDs. Further, out of the 17 metabolites with unique KEGG IDs, 12 metabolites mapped to 78 unique enzyme coding genes (CRPC gene signature). Similarly, the 124 metabolites from the entire data set mapped to 769 enzyme coding genes. On the other hand, in the metabolic signature altered in LNCaP vs C4-2 and LNCaP-abl comparison, 31 metabolites were altered at FDR corrected P value 0.2 out of which 28 mapped to unique KEGG IDs and mapped to 236 unique enzyme coding genes. This entire process of converting metabolites to their corresponding enzyme coding genes was done using in-house Python language scripts.

**Molecular Concept Enrichment Analysis**

We used the Oncomine concept map (OCM) (private. molecularconcepts.org)\(^\text{22}\) to derive enriched bioprocesses or molecular concepts associated with CRPC in a network format. A molecular concept also termed molecular signature is a list of genes or proteins that are derived from various external databases and computationally derived regulatory networks. OCM is composed of more than 14,000 molecular concepts and provides a platform to systematically analyze lists of differentially expressed gene sets. The compendia of molecular concepts for OCM analysis consists of data from 13 databases and 335 high-throughput data sets. The method calculates parameters of association for each individual molecular concept with a gene set (e.g., CRPC gene signature) using Fisher’s exact test. The analysis is carried out using a null set to control for background enrichments. In this study, the CCAMS was used to perform bioprocess enrichment, in the background of 769 genes associated with the set of 150 metabolites examined in this study, as the null set.

Further, as additional controls, we also looked for enriched molecular concepts using five randomly generated gene sets, each containing 78 enzyme coding genes. To generate a random gene signature set, we first subtracted the list of genes associated with CCAMS from the total set of KEGG-derived genes (n = 4435). This resulted in a set of 4357 genes, which were used to generate five independent signatures, each containing 78 genes, after multiple rounds of randomization (n = 10,000). The resulting five random gene sets were used in parallel with CCAMS to perform OCM-based enrichment analysis.

**Gene Expression Data Sets**

We used publicly available gene-expression data obtained from the studies of Glinsky,\(^\text{23}\) Sun,\(^\text{24}\) and Taylor\(^\text{25}\) to assess the predictive value of the CCAMS-derived molecular concepts, with regards to biochemical recurrence. Raw data for the Taylor and Sun studies were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo, with GEO ID GSE21035 and GSE25136 respectively), while the Glinsky data was provided by Dr. Setlur (Department of Pathology, Harvard Medical School, Massachusetts General Hospital). While the Glinsky and Sun studies contained gene expression data generated on the Affymetrix U95Av2 and Affymetrix Human Genome U133A Array platforms respectively, the Taylor data contained expression values generated on the Agilent-014693 Human Genome platform. All the data sets were generated using prostatectomy tissues and contained follow up information on time to treatment failure or biochemical recurrence (BCR), that is to say, PSA failure following radical prostatectomy (i.e., PSA recurrence, a measure of treatment failure).

The Glinsky data contained expression measurements for 12,625 transcripts across 79 discrete prostate tumors (we used gene expression values of 78 samples) of which 37 patients experienced BCR, Sun data contained 14021 transcripts across 79 samples of which 37 patients experienced BCR, and the Taylor data measured the expression of 22,329 transcripts, across 140 individual prostate cancer tissues, of which 36 patients experienced BCR. Data from patients with BCR and no-BCR, from the above three data sets were used for the current analysis. Prior to any downstream analysis, all data sets were log2 transformed and quantile normalized using the R-language “limma” package.

**Survival Analysis**

To evaluate the predictive potential of pathways enriched by CCAMS, we selected the top 10 OCM concepts that were highly interconnected. These 10 molecular concepts described starch and sucrose metabolism, androgen and estrogen metabolism, and pentose and glucuronate conversion and importantly shared a common set of 18 highly redundant genes belonging to the UGT family of transferases.\(^\text{26,27}\) Thus, to examine the predictive value of CCAMS for biochemical recurrence (BCR), genes belonging to the UGT cluster were selected.

These selected genes were combined into a single eigengene, using principal components analysis (PCA). The resulting PCA scores were partitioned into positive and negative values, thus creating a factorial score to signify high or low expression. Then, a Cox proportional hazards model was built, using this factorial score as the predictor and time to BCR as the outcome variable, with censoring corresponding to time-to-recurrence. To select the combination of genes with the best predictive ability for BCR in all the three data sets (Glinsky, Sun, and Taylor), a best subset selection procedure was employed. Thus to begin with, for our PCA analysis, genes were weighted on the basis of their expression profiles across different metastatic samples available in Oncomine.\(^\text{28}\) Following this PCA was applied to subsets of genes, of varying sizes, ranging from 2 to 18 for the UGT family. The PCA-based selection was repeated 10000 times for the UGT gene family. The results of the Cox Proportional Hazard Model that was finally selected, describing the high and low groups, were visualized using Kaplan–Meier (KM) plots. The entire analysis described above was performed using the core package and the “survival” package in the R-language.

**RNA-Seq Data Analysis**

The RNA-Seq data contained gene expression information on 267 prostate cancer tissue samples analyzed at the MCTP
The sequencing data was aligned using TopHat 2.0.8 against the Ensembl 69 GRCh37 human genome build and FPKM (fragments per kilobase of exon per million fragments mapped) was calculated across genes in Ensemble 69 using Cufflinks 2.0.2. Graphs were created using a variety of custom R and python scripts. The data was further log2 transformed and the expression of UGT2B15, UGT2B28, and UGT2A1 as well as their combined median expression was plotted using package “lattice” in R-language.

**RESULTS**

In this study (refer to Figure 1A), we used liquid chromatography−mass spectrometry (LC−MS) to profile metabolic signatures of both androgen-responsive (AD; LNCaP, MDA-PCa-2a, and MDA-PCa-2b) and castration-resistant prostate cancer (CRPC; LNCaP-ABL, C4-2, and 22Rv1) cell lines. Although the AD cells (LNCaP, MDA-PCa-2a, and MDA-PCa-2b) were derived from metastatic sites, they respond to androgen for their growth and sustenance. In contrast, both LNCaP-ABL and C4-2 were originally derived by castration of LNCaP cells and can grow...
independent of androgen levels in the culture medium. 22Rv1, on the other hand, is a unique CRPC cell line that harbors an alternately spliced androgen receptor (AR) termed V7-variant that has been reported in at least 23% of CRPC patients.33 Furthermore, these cells also overexpress SPINK1 that is seen in ∼10% of the PCa patients.34 Overall, these prostate cancer cell lines represent distinct features of metastatic androgen-dependent (AD) tumors that develop castration resistance after androgen ablation therapy.

The mass spectrometry data were examined using different data-preprocessing methods and a commonly altered CRPC signature, termed "Core CRPC-associated metabolic signature" or CCAMS, was determined. This was subsequently used to identify enriched bioprocesses or metabolic pathways, a subset of which was examined in silico, for their predictive power (Figure 1B). Furthermore, enriched pathways were independently verified using metabolic phenotype microarrays (Figure 1A).

**Metabolic Profiling of Prostate-Derived Cell Lines**

We used MRM liquid chromatography–mass spectrometry (LC−MS) to define the metabolic signatures of both AD and CRPC cell lines (outlined in Figure 1A). The targeted mass spectrometry analysis used in this study was monitored for its robustness using both matrix-free standards and pooled matrix controls. The assay platform had a median CV <2.9% for both matrix-free internal standards and liver pool, respectively (Supporting Information Figure S1). A total of 150 metabolites (refer to Supporting Information Table S1 for list of MRM transitions) were measured for their relative steady-state levels (Figure 2A and Supporting Information Table S2). This included mostly polar and midpolar metabolites that were selected from prior prostate cancer publications19,20 and included carbohydrate, amino acid, nucleotide, amino sugar, polyamine, organic acid, fatty acid, and carnitine metabolism. Importantly, each metabolite was identified using two specific transitions that included a qualifier and a quantifier (Supporting Information Table S1). The mass spectrometry data was preprocessed using Mass Hunter software, followed by use of in-house statistical tools (see above), to derive the CRPC-associated metabolic signature. On the basis of the knowledge that the compendia of differential compounds identified by analysis of high-throughput data is sensitive to the data preprocessing steps,35 we examined the AD and CRPC cell line-derived mass spectrometry-derived data, using four different normalization methods, to derive CCAMS (Figure 1A) (refer to Supporting Information Table S1 and Materials and Methods for details). A differential list of metabolites was generated using each of these preprocessing methods (FDR corrected P value <0.2, see Supporting Information Table S3 for the list of differential metabolites for each normalization method). A total of between 40 and 50 metabolites (FDR corrected P value <0.2) were found to be differentially altered in each of these normalization processes, of which 38

---

**Figure 2.** (A) Heat map showing the steady-state levels of 150 metabolites examined using multiple reaction monitoring (MRM)-based targeted profiling of androgen-dependent (AD) and castration-resistant (CRPC) prostate cancer cell lines. Columns correspond to cell lines, and rows correspond to metabolites. Shades of red represent elevated levels of metabolite, and shades of green represent reduced levels of the metabolites (refer to scale for details). (B) Same as in panel A, but showing the list of metabolites that were commonly altered between AD and CRPC cells, across four different data preprocessing methods (termed core CRPC-associated metabolic signature or CCAMS). The heat map shows 38 metabolites that were altered at an FDR corrected P value of 0.2. Color scheme is similar to that in panel A.
compounds were commonly altered in all 4 preprocessing methods. Commonly altered metabolites between AD and CRPC cell lines (FDR corrected P value <0.2), termed core CCAMS, are shown in Figure 2B, while Supporting Information Figures S2–S5 show the distinct metabolic signatures obtained for each of the normalization methods. Out of 38 commonly altered metabolites, levels of 12 compounds were elevated in CRPC, while the remaining 26 metabolites were higher in AD cells. Metabolites elevated in CRPC included sugars such as fructose and galactose, as well as energy/signaling intermediates such as NAD, GMP, AMP, and ADP. Metabolites elevated in AD included carnitines as well as metabolites in the amino sugar or hexose monophosphate pathway. Also, AD cells contained higher levels of methylated metabolites such as methylalanine and dimethylglycine, as well as elevated levels of amino acids, supporting our earlier observation of androgen signaling regulating the methylation axis and amino acid metabolism, in AD cells. We also compared the metabolic signature of LNCaP (AD) with LNCaP-abl and C4-2 (CRPC) cells, which provided further insights into metabolic alterations in AD vs CRPC cells derived from the same parental cell line. There were 31 differential metabolites (FDR corrected P value 0.2) in this comparison, of which 9/31 metabolites were also common to CCAMS (Supporting Information Figure S6A). The common metabolites included galactose, gluconic acid, N-acetyl galactosamine, asparagine, guanosine monophosphate (GMP), amino-butyric acid, 2-oxo-3-methyl valerate, palmitoylcarnitine, and hexonoylcarnitine. Similar to CCAMS, galactose, asparagine, and GMP were elevated in the CRPC cells, whereas gluconic acid, N-acetyl galactosamine, hexonoylcarnitines, and palmitoylcarnitine were elevated in AD cells. Overall, based on the above findings, it appears that CRPC cells tend to generate higher levels of acetyl CoA, NAD, and second messengers, while being inefficient in mitochondrial transport of fatty acid break down intermediates. In contrast, AD cells seem to be more efficient in utilizing amino acids for their survival.

OCM-Based Enrichment Analysis of Altered Metabolites

To obtain better insight into pathways represented in our metabolic data (see Figure 1B), a subset of metabolites associated with the CCAMS (FDR corrected P value <0.06, n = 19) were first mapped to their KEGG IDs, which were then sequentially mapped to their corresponding enzymes and associated gene IDs. Thus, as described in Figure 1B, the 19 differential metabolites were mapped to their KEGG IDs, using the KEGG database (KEGG API version v6.2). All two metabolites mapped to a unique KEGG identifier. The two metabolites that did not map to a KEGG ID, hexanoylcarnitine and ethyl-3-indoleacetate, were not used for further analysis. The KEGG ID’s for the metabolites were then mapped to their corresponding enzyme IDs that were in turn matched up with their gene IDs. Overall, of the 17 metabolites with unique identifiers, 12 compounds mapped to a total of 78 enzyme coding genes (termed CRPC-gene-signature, Supporting Information Table S4). The CCAMS thus generated was used to carry out the OCM-based enrichment analysis. As controls for the enrichment analysis, five random metabolic gene signatures (Supporting Information Table S5), each 78 genes long, were also enriched using OCM. These random gene sets were selected from a pool of 4435 KEGG-associated metabolic genes, after 10,000 independent iterations (see Methods). Notably, when used in OCM, only the CCAMS enriched for significant biochemical processes, while the random metabolic gene signatures did not.

The CCAMS enriched a total of 61 concepts at FDR Q value <0.05 (Supporting Information Table S6). The top 10 pathways enriched by the CCAMS (P value <2 x 10^-05, FDR Q value <0.002; see Supporting Information Table S7 for the list) were then visualized as a network (Figure 3). From these data we observed a tightly interconnected network of molecular concepts (brown bridges) that described gluconosyltransferase activity, pentose and glucuronate interconversions, porphyrin and chlorophyll metabolism, microsome, starch and sucrose metabolism, UDP-glucuronosyl/UDP-glucosyltransferase, androgen and estrogen metabolism, and chromosomal arms 4q13 and 2q37. Interestingly, all these concepts share a common set of genes belonging to the UDP-glucuronosyltransferase (UGT) family. This includes UGT1 (genes n = 9) and UGT2 (genes n = 9). We further investigated the OCM-based pathway enrichment using metabolites that were significantly altered (FDR corrected P value <0.2) between LNCaP and LNCaP-abl/C4-2 cells. The enriched molecular concepts (FDR corrected P value <1 x 10^-05) were clustered into three groups of which one of them described UDP-glucuronosyltransferases (Supporting Information Figure S6B). The other two clusters described enrichment of receptor interaction/activity and metal-dependent phosphodiesterases activity, respectively (Supporting Information Figure S6 B).
Furthermore, the 9 metabolites that were common between CCAMS and our LNCaP vs C42 and LNCaP-abl comparison also enriched for UDP-glucuronosyltransferases along with concepts describing 3-5-cyclic nucleotide and metal-dependent phosphodiesterases activity (Supporting Information Figure S6C).

Importantly, UDP-glucuronosyltransferases and its components have been previously identified in independent studies to play an essential role in prostate cancer progression and therefore reinforce the power of our approach in being able to obtain biologically relevant pathways using bioinformatics analysis of cell line-derived metabolic data sets. We also examined the list of differential metabolites (FDR Q value <0.05) obtained in 3 out of 4 normalization methods, for enriched bioprocesses (Supporting Information Figure S7). Here, in addition to the bioprocesses identified by the CCAMS, we identified a cluster of pathways associated with amino acid metabolism describing those associated with glutamate, alanine, and aspartate metabolism (Supporting Information Figure S7, red bridges) and an independent set of concepts describing galactose and aminosugar metabolism (Supporting Information Figure S7, green bridges).

Next, we examined for any overlap between the cell line-derived CRPC concepts and those obtained from the metastatic tissue-associated metabolic data that we had published earlier. As shown in Supporting Information Figure S8, a total of 7 bioprocesses overlapped between these two data sets, supporting the clinical relevance of our cell line-based findings.

Metabolic Phenotyping Microarray

To ascertain the validity of the pathways identified by OCM analysis, metabolic phenotyping microarrays (MPM) were carried out on AD and CRPC cell lines. The underlying principle of MPM is that the rate of utilization of various metabolites that serve as the sole source of carbon or nitrogen can be determined by measuring the amount of NADH produced over time. The latter is quantified by measuring absorbance of reduced tetrazolium dye at 450 nm. Thus, in MPM, the rate of NADH production is used as a proxy of activity through biochemical pathways that utilize the given metabolite. MPM measured the rate of utilization of 184 (92 amino acids and 92 sugar intermediates) metabolites (Supporting Information Table S8) distributed in two 96-well plates. These metabolites were part of the PMM1 and PMM2 plates marketed by BIOLOG Inc., and were chosen on the basis of our mass spectrometry findings that show alteration in metabolites associated with the sugar and amino acid pathways. Data from these plates were examined using the GSA enrichment-based approach to obtain pathways that were significantly (FDR corrected P value <0.05) altered between CRPC and AD cell lines. A total of 23 metabolic pathways were found to be altered at FDR level of 5% (refer Table 1 for list of altered pathways). Included among the top 9 in this list were fructose and mannose metabolism, galactose metabolism, phenylalanine metabolism, glyoxylate and dicarboxylate metabolism, ABC transporters, amino sugar metabolism, starch and sucrose metabolism, and TCA cycle, among others. Intriguingly, 9/23 altered pathways (shown in bold red fonts in Table 1) were also nominated by the OCM analysis to be associated with CRPC. Thus, OCM and MPM revealed alterations in starch/sucrose metabolism, aminosugar metabolism, pentose phosphate pathway, alanine and aspartate pathway, pentose and glucuronate interconversion, glutamate metabolism, glycolysis, and pyruvate metabolism. This study verifies the robustness of the metabolic pathways defined by mass spectrometry-coupled bioinformatics analysis for CRPC.

Evaluation of the Clinical Relevance of CRPC-Associated Metabolic Pathways

To examine the clinical relevance of the CCAMS-associated metabolic pathways, we carried out an in-silico analysis, looking for any association between the component genes in our identified metabolic pathways enriched in CRPC with BCR. For this association-based analysis, Glinsky, Sun, and Taylor prostate cancer gene expression data sets were used. A summary of the clinical information associated with each of these data sets is provided in Supporting Information Tables S9–S11. These data sets contained approximately 70–140 prostate cancer patients with a median followup time of 54–60 months post-prostatectomy. For the analysis, initially the gene expression values for the metabolic genes associated with CRPC were collected from Glinsky, Sun, and Taylor data sets. Following this, the combination of genes associated with a specific metabolic pathway were examined using principal component analysis (PCA) to derive a threshold value for their average expression that was then used to divide the samples into two groups, namely, those having low or high expression. The association of the low or high group with BCR and hence the ability of the PCA-derived threshold to make this distinction was then examined using a Cox-proportional hazard model, and the results were visualized using Kaplan–Meier (KM) plots (see Materials and Methods for complete description).

For the UDP-glucuronosyltransferase pathway, higher combined expression of three genes, namely, UGT2B15,

Table 1. List of Metabolic Pathways That Showed Significantly (FDR Corrected P-value < 0.05) Altered Activity, in AD vs CRPC Cells, in Metabolic Phenotyping Microarray

<table>
<thead>
<tr>
<th>Pathway</th>
<th>FDR Corrected P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fructose and mannose metabolism</td>
<td>0.005</td>
</tr>
<tr>
<td>Galactose metabolism</td>
<td>0.005</td>
</tr>
<tr>
<td>Phenylalanine metabolism</td>
<td>0.005</td>
</tr>
<tr>
<td>Glyoxylate and dicarboxylate metabolism</td>
<td>0.0007</td>
</tr>
<tr>
<td>Aminosugar metabolism</td>
<td>0.0008</td>
</tr>
<tr>
<td>ABC transporters</td>
<td>0.014</td>
</tr>
<tr>
<td>Starch and sucrose metabolism</td>
<td>0.014</td>
</tr>
<tr>
<td>Citrate cycle (TCA cycle)</td>
<td>0.019</td>
</tr>
<tr>
<td>Pentose phosphate pathway</td>
<td>0.019</td>
</tr>
<tr>
<td>Reductive carbohydrate cycle (C2O2 fixation)</td>
<td>0.019</td>
</tr>
<tr>
<td>Alanine and aspartate metabolism</td>
<td>0.034</td>
</tr>
<tr>
<td>Tyrosine and tryptophan biosynthesis</td>
<td>0.034</td>
</tr>
<tr>
<td>Pyruvate metabolism</td>
<td>0.035</td>
</tr>
<tr>
<td>Pentose and glucuronate interconversion</td>
<td>0.005</td>
</tr>
<tr>
<td>Glutamate metabolism</td>
<td>0.0064</td>
</tr>
<tr>
<td>Beta-alanine and D-alanine metabolism</td>
<td>0.0132</td>
</tr>
<tr>
<td>Pathways in cancer</td>
<td>0.0182</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>0.0152</td>
</tr>
<tr>
<td>Phenyl alanine</td>
<td>0.0189</td>
</tr>
<tr>
<td>Butanone metabolism</td>
<td>0.0372</td>
</tr>
<tr>
<td>Tauurine and hypouracil</td>
<td>0.0415</td>
</tr>
<tr>
<td>Glycolysis/ Gluconeogenesis</td>
<td>0.0445</td>
</tr>
<tr>
<td>Inositol phosphate metabolism</td>
<td>0.0445</td>
</tr>
</tbody>
</table>

*Pathways that are in bold red fonts were also determined to be altered in core CRPC associated metabolic signature (CCAMS) using OCM derived bioprocess enrichment.
UGT2A1, and UGT2B28, was found to be highly associated (P value <0.05 in Glinsky, Sun, and Taylor) with BCR (Figure 4A−C). Furthermore, consistent with this observation, the combined median expression of UGT2B15, UGT2A1, and UGT2B28 was significantly elevated (P value <0.05) in metastatic prostate cancer compared to localized tumors in the Grasso,38 Taylor,25 and Varambally39 gene expression data sets, whereas the expression was not significant due to small sample numbers in the Vanaja40 data set (Figure 4D−G). The clinical relevance of combined expression of UGT2A1, UGT2B15, and UGT2B28 was further validated using a RNA-seq data set containing expression values for 267 prostate cancer tissues, sequenced at the Michigan Center for Translational Pathology, University of Michigan. The 267 tissues included 26 benign adjacent, 93 organ-confined, and 148 metastatic tumors. The metastatic tissues were collected during warm autopsy. Importantly, combined expression of UGT2A1, UGT2B15, and UGT2B28 was significantly higher in metastatic prostate cancer tissues compared to organ-confined disease (P = 1.2 × 10−05, Figure 5D). Further, when examined independently, both UGT2B28 and UGT2B15 were found to be significantly elevated in metastatic disease compared to localized PCa (P < 1 × 10−05, Figure 5AB. Importantly however, genes associated with pathways enriched using randomly generated metabolic

Figure 4. (A−C) Kaplan−Meier plots showing the prognostic value of UDP-glucuronosyltransferases, using the Glinsky, Sun, and Taylor gene expression data sets for prostate cancer.23−25 Time to biochemical recurrence (BCR) was used as the prognostic end point. (D, E) Boxplots showing higher combined expression of UGT2B28, UGT2B15 and UGT2A1 in metastatic PCa compared to organ-confined PCa in Grasso,38 Taylor,25 Varambally,39 and Vanaja40 gene expression data sets. The combined expression of these genes were significantly higher in metastatic tissues, in 3 of 4 data sets examined.

Figure 5. (A−C) Plots showing the relative expression of UGT2B15, UGT2B28, and UGT2A1 measured using RNA-Seq, across 26 benign prostate (green), 93 localized (blue), and 148 metastatic (red) prostate cancer tissues. The Y-axis describes the log 2 values of FPKM (fragments per kilobase of exon per million fragments mapped). (D) Same as in A−C, but for combined median expression of UGT2B15, UGT2B28 and UGT2A1 in the prostate-derived tissue samples.
gene signatures did not show a significant correlation with BCR-based clinical outcome.

**DISCUSSION**

Cancer is a complex disease governed by multiple alterations at the level of transcriptomics, proteomics, and metabolomics. Recent developments in high-throughput technologies have strengthened the methods used for the integration of reproducible data from different platforms to determine a global picture of the pathogenesis of cancer. One such study in breast cancer integrated high-throughput gene-expression and proteomics data with biological network information and determined defining molecular components of breast tumorigenesis.41 This and other similar studies highlight the power of an integrative pathway-centric approach to studying cancer. In the present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.

AR signaling plays a critical role in the development of PCa, by regulating both oncopgenic and metabolic genes.42,43 In our earlier study, we described an AR-regulated metabolic signature in AD PCa, wherein alterations in amino acid metabolism were a key component.20 Clinically, the dependence of PCa on androgen signaling is exploited by the administration of androgen ablation as the first line of treatment for metastatic tumors and those that recur and progress following failed primary treatment (radiation or surgery). For men who receive androgen ablation for metastatic prostate cancer, the median time to development of CRPC is approximately 16–20 months.44,45 In these patients, AR signaling appears to be active and independent of circulating levels of androgen.

Studies from many groups have revealed activating changes in AR such as mutations,47 as well as alterations in the receptor that permit promiscuous activity.48 The earlier study, we described an AR-regulated metabolic signature that such events are often observed.49 In our present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.

AR signaling plays a critical role in the development of PCa, by regulating both oncopgenic and metabolic genes.42,43 In our earlier study, we described an AR-regulated metabolic signature in AD PCa, wherein alterations in amino acid metabolism were a key component.20 Clinically, the dependence of PCa on androgen signaling is exploited by the administration of androgen ablation as the first line of treatment for metastatic tumors and those that recur and progress following failed primary treatment (radiation or surgery). For men who receive androgen ablation for metastatic prostate cancer, the median time to development of CRPC is approximately 16–20 months.44,45 In these patients, AR signaling appears to be active and independent of circulating levels of androgen.

Studies from many groups have revealed activating changes in AR such as mutations,47 as well as alterations in the receptor that permit promiscuous activity.48 The earlier study, we described an AR-regulated metabolic signature that such events are often observed.49 In our present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.

AR signaling plays a critical role in the development of PCa, by regulating both oncopgenic and metabolic genes.42,43 In our earlier study, we described an AR-regulated metabolic signature in AD PCa, wherein alterations in amino acid metabolism were a key component.20 Clinically, the dependence of PCa on androgen signaling is exploited by the administration of androgen ablation as the first line of treatment for metastatic tumors and those that recur and progress following failed primary treatment (radiation or surgery). For men who receive androgen ablation for metastatic prostate cancer, the median time to development of CRPC is approximately 16–20 months.44,45 In these patients, AR signaling appears to be active and independent of circulating levels of androgen.

Studies from many groups have revealed activating changes in AR such as mutations,47 as well as alterations in the receptor that permit promiscuous activity.48 The earlier study, we described an AR-regulated metabolic signature that such events are often observed.49 In our present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.

AR signaling plays a critical role in the development of PCa, by regulating both oncopgenic and metabolic genes.42,43 In our earlier study, we described an AR-regulated metabolic signature in AD PCa, wherein alterations in amino acid metabolism were a key component.20 Clinically, the dependence of PCa on androgen signaling is exploited by the administration of androgen ablation as the first line of treatment for metastatic tumors and those that recur and progress following failed primary treatment (radiation or surgery). For men who receive androgen ablation for metastatic prostate cancer, the median time to development of CRPC is approximately 16–20 months.44,45 In these patients, AR signaling appears to be active and independent of circulating levels of androgen.

Studies from many groups have revealed activating changes in AR such as mutations,47 as well as alterations in the receptor that permit promiscuous activity.48 The earlier study, we described an AR-regulated metabolic signature that such events are often observed.49 In our present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.

AR signaling plays a critical role in the development of PCa, by regulating both oncopgenic and metabolic genes.42,43 In our earlier study, we described an AR-regulated metabolic signature in AD PCa, wherein alterations in amino acid metabolism were a key component.20 Clinically, the dependence of PCa on androgen signaling is exploited by the administration of androgen ablation as the first line of treatment for metastatic tumors and those that recur and progress following failed primary treatment (radiation or surgery). For men who receive androgen ablation for metastatic prostate cancer, the median time to development of CRPC is approximately 16–20 months.44,45 In these patients, AR signaling appears to be active and independent of circulating levels of androgen.

Studies from many groups have revealed activating changes in AR such as mutations,47 as well as alterations in the receptor that permit promiscuous activity.48 The earlier study, we described an AR-regulated metabolic signature that such events are often observed.49 In our present study, we have employed a similar approach but with a distinct method to combine (steady-state levels) data from metabolomics with those from gene expression in a pathway-centric manner and have further validated the (flux) activity of identified pathways using metabolic phenotyping microarrays. Using such an approach, we have determined clinically relevant biochemical pathways that are associated with the development of CRPC, as well as the prediction of primary treatment failure or biochemical recurrence.
in PCA tissues collected at surgery prior to any other treatment could predict time to BCR. When visualized using Kaplan–Meier plots, tumors having higher combined expression of these three genes showed BCR at an earlier time point (i.e., worse outcome) compared to those having lower combined expression levels for these genes. This was validated in 3 of 4 independent gene expression data sets wherein higher combined expression of these UGT-associated genes (UGT2B15, UGT2A1, and UGT2B28) was observed in metastatic PCA compared to organ-confined tumors, a finding that was independently confirmed using a RNA-seq data set. From a larger perspective, these results indicate that monitoring the expression levels of a set of UGT genes could be used as a means to refine treatment tools for men with localized PCA who undergo radical prostatectomy. Our data need to be validated but do, however, demonstrate the potential utility of a cell line derived metabolomic approach to studying human cancer.

In summary, this study, for the first time, defined a cell line-based metabolic signature for CRPC. This signature was then translated into pathways using Oncomine concept map-based enrichment and validated using metabolic phenotyping microarray. Importantly, expression levels of the delineated metabolic pathways in localized PCA appear to correlate with the risk of treatment failure or biochemical recurrence.

■ ASSOCIATED CONTENT

Supporting Information

This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: 713-798-3393. Fax: 713-790-1275. E-mail: sreekuma@bcm.edu.

Author Contributions

▽ These authors contributed equally to this work.

Author Contributions

♦ Equal senior authors.

Notes

The authors declare the following competing financial interest(s): None of the authors except Ismael A. Vergara and Nicholas Erho, have any financial disclosure. Both Ismael A. Vergara and Nicholas Erho are employees of GenomeDx Biosciences, Inc., Vancouver, BC, Canada and were not involved in the study design or data interpretation.

■ ACKNOWLEDGMENTS

We would like to acknowledge Praveen Kumar Akula Sure-shkumar for his assistance in metabolic phenotyping microarray (MPM). This research was supported by the following grant support: NIH 1RO1CA133458-01 (A.S.K.), Susan Komen Foundation Grant KG110818 (A.S.K.), NIH U01 CA167234 (A.S.K., G.P., and G.M.), DOD W81XWH-12-1-0130 (A.S.K., G.P., and G.M.), NSF DMS-1161759 (A.S.K.), NSF DMS-12-28164 (G.M.) and NSF DMS-11617838 (G.M.), RP120092 (A.S.K.), and Funds from the Alkek Center for Molecular Discovery (A.S.K.).

■ REFERENCES


